Ensifentrine(新型PDE3/4双重抑制剂)治疗慢性阻塞性肺疾病:随机双盲安慰剂对照多中心III期试验(ENHANCE试验)
ENHANCE-1和ENHANCE-2两项III期随机双盲安慰剂对照试验评估雾化吸入ensifentrine在中重度症状性COPD患者中的疗效。共随机治疗760例(ENHANCE-1)和789例(ENHANCE-2)患者。两项试验均显示ensifentrine显著改善肺功能(FEV1 AUC0-12h较安慰剂提高87 ml和94 ml,均P<0.001),并降低中重度急性加重率(ENHANCE-1 RR 0.64,P=0.050;ENHANCE-2 RR 0.57,P=0.009),不良事件发生率与安慰剂相似。
要点
- ensifentrine显著改善COPD患者肺功能,两项试验FEV1 AUC0-12h分别提高87 ml和94 ml。
- ensifentrine降低中重度急性加重率并延长首次加重时间,ENHANCE-2达统计学显著。
- ensifentrine安全性与安慰剂相似,可作为COPD维持治疗的附加选择。
核心结论
- ensifentrine在两项III期试验中均显著改善COPD患者肺功能,并支持降低急性加重率和风险,可在广泛COPD人群及其他维持治疗基础上使用。
研究设计与样本
- 两项III期、多中心、随机、双盲、平行组、安慰剂对照试验(ENHANCE-1和ENHANCE-2),于2020年9月至2022年12月在17个国家250个研究中心和呼吸科诊所进行。
- 纳入40-80岁中重度症状性COPD患者,ENHANCE-1随机治疗760例,ENHANCE-2随机治疗789例。
主要发现
- ENHANCE-1中ensifentrine在第24周显著改善症状(E-RS)和生活质量(SGRQ),ENHANCE-2中未达显著。
- ensifentrine较安慰剂降低24周中重度急性加重率:ENHANCE-1率比0.64(95%CI 0.40,1.00),P=0.050;ENHANCE-2率比0.57(95%CI 0.38,0.87),P=0.009。
- ensifentrine延长首次急性加重时间:ENHANCE-1风险比0.62(95%CI 0.39,0.97),P=0.038;ENHANCE-2风险比0.58(95%CI 0.38,0.87),P=0.009。
- 不良事件发生率与安慰剂相似。
临床怎么用
- 对于中重度症状性COPD患者,ensifentrine可作为附加维持治疗选择,改善肺功能并降低急性加重风险。
- ensifentrine可与长效抗胆碱能药或长效β2受体激动剂等其他维持治疗联合使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Rationale: Ensifentrine is a novel, selective, dual phosphodiesterase (PDE)3 and PDE4 inhibitor with bronchodilator and antiinflammatory effects. Replicate phase III trials of nebulized ensifentrine were conducted (ENHANCE-1 and ENHANCE-2) to assess these effects in patients with chronic obstructive pulmonary disease (COPD). Objectives: To evaluate the efficacy of ensifentrine compared with placebo for lung function, symptoms, quality of life, and exacerbations in patients with COPD. Methods: These phase III, multicenter, randomized, double-blind, parallel-group, placebo-controlled trials were conducted between September 2020 and December 2022 at 250 research centers and pulmonology practices in 17 countries. Patients aged 40-80 years with moderate to severe symptomatic COPD were enrolled. Measurements and Main Results: Totals of 760 (ENHANCE-1) and 789 (ENHANCE-2) patients were randomized and treated, with 69% and 55% receiving concomitant long-acting muscarinic antagonists or long-acting β2-agonists, respectively. Post-bronchodilator FEV1 percentage predicted values were 52% and 51% of predicted normal. Ensifentrine treatment significantly improved average FEV1 area under the curve at 0-12 hours versus placebo (ENHANCE-1, 87 ml [95% confidence interval, 55, 119]; ENHANCE-2, 94 ml [65, 124]; both P < 0.001). Ensifentrine treatment significantly improved symptoms (Evaluating Respiratory Symptoms) and quality of life (St. George's Respiratory Questionnaire) versus placebo at Week 24 in ENHANCE-1 but not in ENHANCE-2. Ensifentrine treatment reduced the rate of moderate or severe exacerbations versus placebo over 24 weeks (ENHANCE-1, rate ratio, 0.64 [0.40, 1.00]; P = 0.050; ENHANCE-2, rate ratio, 0.57 [0.38, 0.87]; P = 0.009) and increased time to first exacerbation (ENHANCE-1, hazard ratio, 0.62 [0.39, 0.97]; P = 0.038; ENHANCE-2, hazard ratio, 0.58 [0.38, 0.87]; P = 0.009). Adverse event rates were similar to those for placebo. Conclusions: Ensifentrine significantly improved lung function in both trials, with results supporting exacerbation rate and risk reduction in a broad COPD population and in addition to other classes of maintenance therapies. Clinical trial registered with www. CLINICALTRIALS: gov and EudraCT (ENHANCE-1, www. CLINICALTRIALS: gov identifier NCT04535986, EudraCT identifier 2020-002086-34; ENHANCE-2, www. CLINICALTRIALS: gov identifier NCT04542057, EudraCT identifier 2020-002069-32).
引用
- Anzueto, Barjaktarevic, Siler, et al. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023. PMID: 37364283. doi:10.1164/rccm.202306-0944OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。